China Biopharmaceuticals Market Size and Forecast by Offerings, Therapeutic Area, and Distribution Channel: 2019-2034

China's NRDL Procurement Architecture Concentrates Biosimilar Formulary Access

Unlike most major biopharmaceutical markets where reimbursement and procurement operate as sequential but structurally separate decisions, China's National Reimbursement Drug List negotiation process — administered by the National Healthcare Security Administration — fuses pricing negotiation and formulary access into a single institutional gate. Successive NRDL inclusion rounds since 2024 have compressed originator biologic net prices substantially, redirecting hospital formulary demand toward domestically manufactured biosimilars and locally developed monoclonal antibodies that enter negotiations already positioned at price points originators cannot match without accepting margins that undermine their global reference pricing structures. The more consequential outcome is not simply price compression but a structural concentration of formulary access among domestic producers, particularly in the monoclonal antibody and recombinant protein segments where Chinese manufacturers have built the deepest biosimilar pipelines.

Domestic companies such as BeiGene and CSPC Pharmaceutical are structurally advantaged within this procurement architecture because their cost bases allow NRDL-aligned pricing without the reference price exposure that constrains multinational originators. Having secured both domestic approval and NRDL inclusion for key oncology biologics, these manufacturers capture the hospital channel demand that volume-based procurement concentrates toward lowest-compliant-price suppliers. For multinational participants in the China biopharmaceuticals sector, the NHSA negotiation cycle now functions as the primary commercial differentiator — not regulatory authorization, which many have already secured, but the ability to sustain viable net pricing inside a procurement mechanism designed to extract annual concessions across successive negotiation rounds.

NRDL Inclusion Cycles Concentrate Hospital Formulary Demand Domestically

What the surface pricing data understates is the formulary concentration effect that successive National Reimbursement Drug List negotiation rounds have produced at the hospital procurement level — a mechanism distinct from price reduction itself. Because NRDL inclusion simultaneously determines reimbursement eligibility and hospital formulary positioning, domestic biosimilar manufacturers whose cost structures accommodate negotiated price floors gain formulary placement that originator biologics, constrained by global reference pricing obligations, cannot competitively match without triggering parallel reimbursement adjustments in other markets. Hospital procurement committees operating under the National Healthcare Security Administration's cost-containment directives consequently draw down originator biologic volumes in favour of NRDL-listed domestic equivalents, concentrating institutional purchasing toward domestic producers in the monoclonal antibody and recombinant protein segments. The less visible directional consequence is that each successive NRDL negotiation round deepens this structural concentration, raising the formulary share captured by domestically manufactured biologics and making re-entry for non-compliant originators increasingly capital-intensive relative to the addressable reimbursed volume remaining.

Inside China's NRDL Concentration Engine for Biosimilar Producers

Domestic biosimilar manufacturers capable of meeting NRDL-compliant price floors now hold a structurally reinforced formulary position that widens with each successive negotiation cycle. The mechanism is self-compounding: hospital procurement committees operating under National Healthcare Security Administration cost-containment mandates progressively substitute originator biologics with NRDL-listed domestic equivalents, expanding the addressable reimbursed volume available exclusively to compliant domestic producers. Vendors whose manufacturing cost structures already accommodate NRDL-negotiated price levels — particularly in the monoclonal antibody and recombinant protein segments — gain formulary share without proportionate competitive exposure, as the entry cost for non-compliant originators to recapture that institutional volume rises after each successive round.

Biosimilar Formulary Gains Mask Worsening Pipeline Concentration Risk

Capital allocation within the China biopharmaceuticals sector has increasingly flowed toward late-stage biosimilar development targeting National Reimbursement Drug List-eligible indications, where formulary access is structurally assured for compliant domestic manufacturers — while early-stage differentiated biologic investment, which carries higher regulatory uncertainty and longer return horizons, attracts proportionately less domestic venture and institutional funding. The mechanism producing this distortion is the NRDL negotiation architecture itself: because formulary inclusion is the dominant determinant of commercial volume at hospital level, manufacturers rationally concentrate development resources in segments where NRDL-compliant pricing is achievable, narrowing the active pipeline toward existing biosimilar categories rather than novel biologic modalities such as cell therapies, gene therapies, and RNA therapeutics. Hospital procurement committees and the domestic manufacturers supplying them consequently face an emerging structural fragility — the portfolio of NRDL-reimbursed biologics is deepening within a narrow therapeutic band rather than broadening across modalities, which, as the pipeline matures, is likely to compress differentiation and compress margins simultaneously. The more consequential risk is that a procurement architecture optimised to accelerate biosimilar substitution may, in practice, systematically underfund the next generation of advanced biologic categories that China's National Medical Products Administration has yet to see submitted in volume.

China's Domestic Players Bet on NRDL — and Now Lead Formulary Volume

Formulary concentration rather than pipeline breadth defines competitive positioning across the China biopharmaceuticals sector, and established domestic manufacturers have structured their commercial strategies around precisely that dynamic. Innovent Biologics, Jiangsu Hengrui Pharmaceuticals, BeOne Medicines (formerly BeiGene), and CSPC Pharmaceutical each maintain portfolios weighted toward NRDL-eligible biologics spanning monoclonal antibodies, recombinant proteins, and oncology-focused therapeutic categories, giving them collective institutional access that originators constrained by global reference pricing cannot replicate at comparable volume.

The field-level strategic pattern among leading providers has been disciplined NRDL alignment rather than portfolio diversification. Innovent Biologics secured product inclusions in recent NRDL negotiation cycles spanning oncology, recombinant antibody, and metabolic indications, which expanded its hospital formulary reach without proportionate additional commercialisation cost. Jiangsu Hengrui, whose pipeline ranked among the top globally in active drug candidates, has similarly concentrated late-stage development in NRDL-eligible therapeutic segments. Sichuan Kelun-Biotech entered a cross-territorial partnership with Crescent Biopharma to advance a PD-1 × VEGF bispecific antibody and an antibody-drug conjugate — retaining Greater China rights while externalising development cost for ex-China territories, a model that preserves domestic NRDL positioning while redistributing capital risk. Major multinational operators have also entered structural agreements with domestic partners as part of a broader licensing architecture, reflecting how even global players now anchor China commercialisation strategies around domestic partners with established NRDL negotiation capability.

The competitive consequence of this field-level alignment is that the China National Reimbursement Drug List negotiation process has functionally become the primary mechanism through which formulary share is allocated — and domestic manufacturers whose cost structures were already calibrated to NRDL-compliant price floors have converted each successive cycle into a structural barrier against late-entering or price-constrained competitors, compounding their institutional volume advantage with every negotiation round.